Dongwoon Anatech Introduces Saliva Glucose Measurement Technology at European Association for the Study of Diabetes

[Asia Economy Reporter Hyungsoo Park] Dongwoon Anatech announced on the 6th that it will introduce the diagnostic device ‘D-SaLife,’ which uses saliva-based glucose measurement technology, at the European Association for the Study of Diabetes (EASD).

The European Association for the Study of Diabetes is a global diabetes conference attended by about 20,000 diabetes-related doctors, healthcare professionals, and medical companies from over 130 countries. The conference is held every September in major European cities. This year, it will take place from September 19 to 23 in Stockholm, Sweden. Doctors and healthcare workers related to diabetes present their academic research results. This year, for the first time among domestic medical device companies, Dongwoon Anatech’s ‘D-SaLife’ research paper was selected as a presentation paper.

A Dongwoon Anatech official stated, "At the European Association for the Study of Diabetes, Professor Min Kyungwan, who led the clinical research, will present on the ‘saliva-based glucose measurement technology and diagnostic device product.’"

The saliva-based glucose meter showed accuracy and correlation levels similar to those of conventional blood sampling-based glucose meters. In 2020, Dongwoon Anatech conducted a clinical trial on the saliva-based diabetes diagnostic device with 114 patients. They succeeded in producing results within the error range recognized by the Ministry of Food and Drug Safety. The potential as a diabetes diagnostic device was confirmed.

Dongwoon Anatech expects that the saliva-based glucose measurement device (D-SaLife) under development will be competitive due to its non-invasive method without the pain of blood sampling. It enables diabetes management essential for early diagnosis and prevention. The core technology is accurately quantifying glucose in saliva, which is 50 times more diluted than blood and difficult to detect, using microcurrent technology. Over the past six years, the product has been improved through exploratory clinical trials and in-house pilot tests. Variables sensitive to changes in conditions such as various interfering substances generated from human saliva and temperature have been eliminated, developing the product to a stage ready for commercialization. Currently, patents have been registered in Korea, China, and Japan. Patent applications are pending in the United States, India, and Europe.